Janssen gets European green light for antipsychotic drug delivery

Janssen-Cilag International, a Johnson & Johnson company, has received approval from the European Commission for the first antipsychotic treatment for schizoaffective disorder. INVEGA (paliperidone ER) can now treat patients with psychotic or manic symptoms of schizoaffective disorder. INVEGA was first approved in Europe in June 2007 for the treatment of schizophrenia. It's delivered via an osmotic drug delivery system that provides a steady, smooth release of medication over 24 hours.

"Janssen is committed to helping improve the lives of people with serious mental illness and has a long history of developing innovative medicines in this field," Dr. Christophe Tessier, psychiatric medical affairs director at Janssen, said in a statement. "We are proud to be able to bring to market the first antipsychotic treatment for schizoaffective disorder in Europe--a difficult to diagnose condition associated with a high rate of hospitalizations and suicidal behavior."

The approval is based on two international, randomised, double-blind, placebo-controlled six-week studies in patients diagnosed with schizoaffective disorder.

- read the Janssen release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.